SpeeDx Company

SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
Technology: diagnostics
Industry: Biotechnology, Health Diagnostics, Medical
Headquarters: Sydney, New South Wales, Australia
Founded Date: 39814
Employees Number: 11-50
Funding Status: Early Stage Venture
Estimated Revenue: $1M to $10M
Last Funding Date: 2020-02-12
Last Funding Type: Series B

Visit Website
Register and Claim Ownership